<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-28290" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Vancomycin Flushing Syndrome</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Martel</surname>
            <given-names>Thomas J.</given-names>
          </name>
          <aff>University of South Carolina</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Jamil</surname>
            <given-names>Radia T.</given-names>
          </name>
          <aff>Allama Iqbal Medical College</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>King</surname>
            <given-names>Kevin C.</given-names>
          </name>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Thomas Martel declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Radia Jamil declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Kevin King declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>25</day>
          <month>1</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-28290.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Vancomycin flushing syndrome (VFS), previously known as red man syndrome, is an anaphylactoid reaction caused by the rapid infusion of the glycopeptide antibiotic vancomycin. VFS consists of a pruritic, erythematous rash of the face, neck, and upper torso, which may also involve the extremities, though to a lesser degree. Symptoms may include weakness, angioedema, and chest or back pain. VFS is caused by vancomycin through the direct and non-immune-mediated histamine release from mast cells and basophils. The amount of histamine released is generally related to the dosage of vancomycin infused and the infusion rate. VFS is generally associated with more rapid infusion rates but can be seen following slower infusion rates and after several days of transfusion. Practitioners using vancomycin should be aware of this drug reaction, its prevention, and treatment. This activity describes the evaluation, diagnosis, and management of vancomycin flushing syndrome and stresses the role of team-based interprofessional care for affected patients.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the etiology of vancomycin flushing syndrome.</p></list-item><list-item><p>Interpret the evaluation of vancomycin flushing syndrome.</p></list-item><list-item><p>Evaluate&#x000a0;the treatment and management options available for vancomycin flushing syndrome.</p></list-item><list-item><p>Communicate&#x000a0;interprofessional team strategies for optimizing care coordination to advance the treatment of vancomycin flushing syndrome and improve outcomes.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=28290&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=28290">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-28290.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Vancomycin flushing syndrome (VFS) is an anaphylactoid&#x000a0;reaction&#x000a0;caused by the&#x000a0;rapid infusion of the glycopeptide antibiotic vancomycin. VFS consists of a pruritic,&#x000a0;erythematous rash to the face, neck, and upper torso, which may also&#x000a0;involve the extremities&#x000a0;to a lesser degree. Symptoms may include weakness, angioedema, and chest or back pain. VFS is&#x000a0;caused by vancomycin through the direct and non-immune-mediated histamine release from mast cells and basophils. The amount of histamine&#x000a0;released&#x000a0;is&#x000a0;generally&#x000a0;related to the dose of vancomycin infused and the infusion rate. VFS is generally associated with more rapid infusion rates but can be seen following slower infusion rates and after several days of transfusion. Practitioners&#x000a0;using vancomycin should know this reaction, its prevention, and treatment.<xref ref-type="bibr" rid="article-28290.r1">[1]</xref><xref ref-type="bibr" rid="article-28290.r2">[2]</xref><xref ref-type="bibr" rid="article-28290.r3">[3]</xref></p>
      </sec>
      <sec id="article-28290.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>VFS most frequently occurs with&#x000a0;intravenous vancomycin but may rarely occur from oral or intraperitoneal vancomycin.<xref ref-type="bibr" rid="article-28290.r4">[4]</xref><xref ref-type="bibr" rid="article-28290.r5">[5]</xref><xref ref-type="bibr" rid="article-28290.r6">[6]</xref> It is often related to a&#x000a0;rapid infusion rate of vancomycin (1 gram in less than 1 hour). The current treatment recommendations&#x000a0;are to&#x000a0;administer vancomycin at a rate no faster than 1 gram/hour or 10 mg/min. VFS most often begins 4 to 10 minutes from the start&#x000a0;of the first dose of&#x000a0;intravenous&#x000a0;vancomycin. It may occur later during the infusion or begin shortly after dose completion. VFS may occur from later doses as far out as&#x000a0;7 days.<xref ref-type="bibr" rid="article-28290.r1">[1]</xref><xref ref-type="bibr" rid="article-28290.r2">[2]</xref>&#x000a0;The increased incidence of methicillin/oxacillin-resistant <italic toggle="yes">Staphylococcus aureus</italic>, multiresistant <italic toggle="yes">Staphylococcus&#x000a0;epidermidis</italic>, penicillin-resistant <italic toggle="yes">Streptococcus pneumoniae</italic>, and metronidazole-resistant <italic toggle="yes">Clostridium difficile</italic>&#x000a0;has led to an increase in the use of vancomycin. Vancomycin is commonly used to&#x000a0;treat bacterial endocarditis, abscesses with cellulitis, postoperative wound infections, infected surgically placed devices, and central line-associated bloodstream infections.<xref ref-type="bibr" rid="article-28290.r7">[7]</xref><xref ref-type="bibr" rid="article-28290.r2">[2]</xref>&#x000a0;There are case studies of VFS occurring from other antibiotics such as rifampin, cefepime, teicoplanin, ciprofloxacin, and amphotericin B.<xref ref-type="bibr" rid="article-28290.r3">[3]</xref><xref ref-type="bibr" rid="article-28290.r8">[8]</xref><xref ref-type="bibr" rid="article-28290.r9">[9]</xref><xref ref-type="bibr" rid="article-28290.r1">[1]</xref></p>
      </sec>
      <sec id="article-28290.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>VFS is the most frequent adverse reaction to&#x000a0;intravenous&#x000a0;vancomycin. It occurs in 4% to 50% of infected patients treated with&#x000a0;intravenous vancomycin. Patients under 40 years of age are at the greatest risk of severe VFS reactions. Severe reactions include angioedema, hypotension, tachycardia, weakness, muscle spasms, and chest&#x000a0;or back pain, in addition to a rash of the face, neck, and upper torso. VFS is usually mild and easily managed. There are rare cases of life-threatening VFS reactions.<xref ref-type="bibr" rid="article-28290.r1">[1]</xref></p>
      </sec>
      <sec id="article-28290.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Vancomycin was discovered in 1952 in soil obtained from the jungles of Borneo.&#x000a0;Initial&#x000a0;preparations of the antibiotic lacked&#x000a0;purification and were brown. Therefore, many referred to vancomycin as "Mississippi&#x000a0;mud." Clinicians initially thought VFS, otic, and renal toxicity were secondary to impurities in vancomycin. However,&#x000a0;even after vancomycin was purified, VFS continued to be observed. Animal and several human studies indicate vancomycin activates the degranulation of mast cells and basophils, increasing histamine release. The amount of histamine release has been correlated with the dose and the rate of vancomycin infusion. However, not all studies correlate&#x000a0;elevated histamine levels with severe cases of VFS and suggest histamine&#x000a0;metabolism may also be delayed due to inhibition&#x000a0;of histamine N-methyltransferase&#x000a0;and diamine oxidase enzymes.<xref ref-type="bibr" rid="article-28290.r7">[7]</xref><xref ref-type="bibr" rid="article-28290.r1">[1]</xref></p>
      </sec>
      <sec id="article-28290.s6" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>The clinical presentation of VFS can vary, ranging from minor pruritus to occasionally&#x000a0;life-threatening&#x000a0;symptoms. Symptoms may occur as soon as&#x000a0;4 minutes after initiating&#x000a0;the first dose until&#x000a0;up to&#x000a0;7 days after dose completion. Patients with infections treated with&#x000a0;intravenous vancomycin are at risk of developing VFS. The signs and symptoms of VFS include:<xref ref-type="bibr" rid="article-28290.r1">[1]</xref><xref ref-type="bibr" rid="article-28290.r2">[2]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>Erythematous rash on the face, neck, and upper torso</p>
          </list-item>
          <list-item>
            <p>Nausea, vomiting</p>
          </list-item>
          <list-item>
            <p>Pruritis</p>
          </list-item>
          <list-item>
            <p>Hypotension</p>
          </list-item>
          <list-item>
            <p>Fever, chills</p>
          </list-item>
          <list-item>
            <p>Weakness, dizziness</p>
          </list-item>
          <list-item>
            <p>Chest or back pain, trunk muscle spasms</p>
          </list-item>
          <list-item>
            <p>Angioedema</p>
          </list-item>
          <list-item>
            <p>Tachycardia</p>
          </list-item>
          <list-item>
            <p>Rash on the extremities may occur but is typically less severe than the rash on the face, neck, and upper torso<xref ref-type="bibr" rid="article-28290.r1">[1]</xref><xref ref-type="bibr" rid="article-28290.r2">[2]</xref>&#x000a0;</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-28290.s7" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>The diagnosis of VFS is made clinically and does not depend on laboratory or other tests. Severe cases should be differentiated&#x000a0;from IgE-mediated anaphylactic&#x000a0;reactions.<xref ref-type="bibr" rid="article-28290.r2">[2]</xref></p>
      </sec>
      <sec id="article-28290.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>When a patient develops VFS, the&#x000a0;intravenous antibiotic infusion should be stopped immediately. Supportive care should be provided. H1 (diphenhydramine) and H2 antihistamines (cimetidine) manage VFS. In most cases, future doses of vancomycin may be given at decreased infusion rates.<xref ref-type="bibr" rid="article-28290.r1">[1]</xref>&#x000a0;Mild cases (flushing and pruritus) can be managed with antihistamines such as diphenhydramine 50 mg by mouth or intravenously and cimetidine 300 mg intravenously. Most episodes will resolve within 20 minutes, and the vancomycin may be restarted at 50% of the original rate. Future doses should be given at the new, slower rate, typically over&#x000a0;2 hours.<xref ref-type="bibr" rid="article-28290.r10">[10]</xref>&#x000a0;Moderate to severe cases (severe rash, hypotension, tachycardia, chest pain, back pain, muscle spasms, weakness, angioedema)&#x000a0;should&#x000a0;be managed according to severity. Patients with severe symptoms should be evaluated for anaphylaxis or other serious causes for their symptoms&#x000a0;before assuming VFS. If, after careful&#x000a0;evaluation, the patient is determined to have VFS, antihistamines such as diphenhydramine and cimetidine can both be started intravenously. Normal saline intravenous boluses are used to treat hypotension. After the symptoms resolve, the vancomycin can be restarted and given over&#x000a0;4 hours. If alternative antibiotics to vancomycin are available, they should be used. If vancomycin must be continued, patients should be premedicated with diphenhydramine 50 mg&#x000a0;intravenously&#x000a0;and cimetidine 300 mg&#x000a0;intravenously&#x000a0;1 hour before each dose, and vancomycin should be administered over&#x000a0;4 hours under close observation.<xref ref-type="bibr" rid="article-28290.r11">[11]</xref><xref ref-type="bibr" rid="article-28290.r12">[12]</xref></p>
        <p>Suppose the symptoms of anaphylaxis are present, such as altered mental status, hypotension, stridor, difficulty breathing, wheezing, and hives. In that case, treatment&#x000a0;should&#x000a0;be started&#x000a0;immediately for anaphylaxis, and the patient should need emergency care. Epinephrine should be given early, and the patient may have an epinephrine auto-injector, which can be used.<xref ref-type="bibr" rid="article-28290.r11">[11]</xref><xref ref-type="bibr" rid="article-28290.r12">[12]</xref>&#x000a0;Emergency medical services, if available, should be activated immediately to expedite further patient treatment and transport to definitive care. Patients requiring a rapid infusion of vancomycin may be pre-treated with diphenhydramine and cimetidine. However, the best preventive measure to avoid VFS is maintaining infusion rates below 10 mg/min.<xref ref-type="bibr" rid="article-28290.r13">[13]</xref><xref ref-type="bibr" rid="article-28290.r14">[14]</xref></p>
      </sec>
      <sec id="article-28290.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>VFS should be differentiated from an anaphylactic&#x000a0;reaction. VFS and anaphylactic&#x000a0;reactions&#x000a0;will have similar findings of pruritus, erythematous&#x000a0;rash, and tachycardia. Anaphylactic&#x000a0;reactions involve stridor, angioedema, hives, and wheezing from bronchospasm. Anaphylactic&#x000a0;reactions are IgE-mediated and require prior exposure. VFS is a rate-related anaphylactoid adverse reaction that most often occurs during the first exposure to&#x000a0;intravenous vancomycin.<xref ref-type="bibr" rid="article-28290.r11">[11]</xref><xref ref-type="bibr" rid="article-28290.r12">[12]</xref></p>
      </sec>
      <sec id="article-28290.s10" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>The prognosis for patients with VFS is excellent, with appropriate&#x000a0;management. Vancomycin may be used again after an episode of VFS. Appropriate precautions and treatment guidelines should be followed. Normal&#x000a0;intravenous&#x000a0;saline should be used to treat hypotension,&#x000a0;and other supportive care measures should be provided.</p>
      </sec>
      <sec id="article-28290.s11" sec-type="Complications">
        <title>Complications</title>
        <p>VFS is caused by antibiotics such as vancomycin releasing histamine from basophils and mast cells. Symptoms include a red rash, hypotension, tachycardia, angioedema, and others. Although most cases are manageable, some can be life-threatening.</p>
      </sec>
      <sec id="article-28290.s12" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>To improve patient outcomes, healthcare providers should be made aware of the presentation of VFS and the management of this condition. Patients should receive the most appropriate care and be educated on the condition.</p>
      </sec>
      <sec id="article-28290.s13" sec-type="Pearls and Other Issues">
        <title>Pearls and Other Issues</title>
        <p>Key facts to keep in might about vancomycin flushing syndrome are as follows:</p>
        <list list-type="bullet">
          <list-item>
            <p>VFS is a common adverse reaction seen with intravenous vancomycin use.</p>
          </list-item>
          <list-item>
            <p>The increased use of vancomycin will likely cause an increase in the number of VFS reactions.</p>
          </list-item>
          <list-item>
            <p>Healthcare providers should be aware of this common reaction, its signs and symptoms, and how to manage cases when they occur.</p>
          </list-item>
          <list-item>
            <p>The rapid infusion of vancomycin should be avoided as this most often is a rate-related adverse drug reaction.</p>
          </list-item>
          <list-item>
            <p>Facilities should establish infusion protocols to&#x000a0;limit infusion rates of&#x000a0;vancomycin to 1 gram/hour or slower at 10 mg/min.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-28290.s14" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>To help&#x000a0;maximize patient care&#x000a0;and patient safety, it is important&#x000a0;for the healthcare team to:</p>
        <list list-type="bullet">
          <list-item>
            <p>Recognize early if a patient needs pre-treatment for vancomycin. Patients should be asked if they have had any issues with vancomycin infusion in the past.</p>
          </list-item>
          <list-item>
            <p>Ensure that there is ongoing surveillance of patient response to treatment and an appropriate&#x000a0;handover at shift change to minimize errors during ongoing transfusion</p>
          </list-item>
          <list-item>
            <p>If you have a question about the patient's response to treatment or dose, ask the supervisor or the physician or healthcare provider who prescribed the medication.</p>
          </list-item>
          <list-item>
            <p>Ask pharmacists about the medication and how it should be restarted.</p>
          </list-item>
          <list-item>
            <p>Be familiar with the infusion protocols for the healthcare facility where they work.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-28290.s15">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=28290&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=28290">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/medications/vancomycin-flushing-syndrome/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=28290">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/28290/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=28290">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-28290.s16">
        <title>References</title>
        <ref id="article-28290.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sivagnanam</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Deleu</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Red man syndrome.</article-title>
            <source>Crit Care</source>
            <year>2003</year>
            <month>Apr</month>
            <volume>7</volume>
            <issue>2</issue>
            <fpage>119</fpage>
            <page-range>119-20</page-range>
            <pub-id pub-id-type="pmid">12720556</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28290.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bruniera</surname>
                <given-names>FR</given-names>
              </name>
              <name>
                <surname>Ferreira</surname>
                <given-names>FM</given-names>
              </name>
              <name>
                <surname>Saviolli</surname>
                <given-names>LR</given-names>
              </name>
              <name>
                <surname>Bacci</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Feder</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>da Luz Gon&#x000e7;alves Pedreira</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sorgini Peterlini</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Azzalis</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Campos Junqueira</surname>
                <given-names>VB</given-names>
              </name>
              <name>
                <surname>Fonseca</surname>
                <given-names>FL</given-names>
              </name>
            </person-group>
            <article-title>The use of vancomycin with its therapeutic and adverse effects: a review.</article-title>
            <source>Eur Rev Med Pharmacol Sci</source>
            <year>2015</year>
            <month>Feb</month>
            <volume>19</volume>
            <issue>4</issue>
            <fpage>694</fpage>
            <page-range>694-700</page-range>
            <pub-id pub-id-type="pmid">25753888</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28290.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Panos</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Watson</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Sargianou</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kampiotis</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Chra</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Red man syndrome adverse reaction following intravenous infusion of cefepime.</article-title>
            <source>Antimicrob Agents Chemother</source>
            <year>2012</year>
            <month>Dec</month>
            <volume>56</volume>
            <issue>12</issue>
            <fpage>6387</fpage>
            <page-range>6387-8</page-range>
            <pub-id pub-id-type="pmid">22948884</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28290.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Domis</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Moritz</surname>
                <given-names>ML</given-names>
              </name>
            </person-group>
            <article-title>Red man syndrome following intraperitoneal vancomycin in a child with peritonitis.</article-title>
            <source>Front Pediatr</source>
            <year>2014</year>
            <volume>2</volume>
            <fpage>55</fpage>
            <pub-id pub-id-type="pmid">24926475</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28290.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bergeron</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Boucher</surname>
                <given-names>FD</given-names>
              </name>
            </person-group>
            <article-title>Possible red-man syndrome associated with systemic absorption of oral vancomycin in a child with normal renal function.</article-title>
            <source>Ann Pharmacother</source>
            <year>1994</year>
            <month>May</month>
            <volume>28</volume>
            <issue>5</issue>
            <fpage>581</fpage>
            <page-range>581-4</page-range>
            <pub-id pub-id-type="pmid">8068993</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28290.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bailey</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Gray</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>An elderly woman with 'Red Man Syndrome' in association with oral vancomycin therapy: a case report.</article-title>
            <source>Cases J</source>
            <year>2008</year>
            <month>Aug</month>
            <day>18</day>
            <volume>1</volume>
            <issue>1</issue>
            <fpage>111</fpage>
            <pub-id pub-id-type="pmid">18710566</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28290.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Griffith</surname>
                <given-names>RS</given-names>
              </name>
            </person-group>
            <article-title>Introduction to vancomycin.</article-title>
            <source>Rev Infect Dis</source>
            <year>1981</year>
            <season>Nov-Dec</season>
            <volume>3 suppl</volume>
            <fpage>S200</fpage>
            <page-range>S200-4</page-range>
            <pub-id pub-id-type="pmid">7043707</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28290.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dubettier</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Boibieux</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lagable</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Crevon</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Peyramond</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Milon</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Red man syndrome with teicoplanin.</article-title>
            <source>Rev Infect Dis</source>
            <year>1991</year>
            <season>Jul-Aug</season>
            <volume>13</volume>
            <issue>4</issue>
            <fpage>770</fpage>
            <pub-id pub-id-type="pmid">1833809</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28290.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ellis</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Tharpe</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>Red man syndrome associated with amphotericin B.</article-title>
            <source>BMJ</source>
            <year>1990</year>
            <month>Jun</month>
            <day>02</day>
            <volume>300</volume>
            <issue>6737</issue>
            <fpage>1468</fpage>
            <pub-id pub-id-type="pmid">2379017</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28290.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Korman</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Turnidge</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Grayson</surname>
                <given-names>ML</given-names>
              </name>
            </person-group>
            <article-title>Risk factors for adverse cutaneous reactions associated with intravenous vancomycin.</article-title>
            <source>J Antimicrob Chemother</source>
            <year>1997</year>
            <month>Mar</month>
            <volume>39</volume>
            <issue>3</issue>
            <fpage>371</fpage>
            <page-range>371-81</page-range>
            <pub-id pub-id-type="pmid">9096187</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28290.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Irani</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Akl</surname>
                <given-names>EG</given-names>
              </name>
            </person-group>
            <article-title>Management and Prevention of Anaphylaxis.</article-title>
            <source>F1000Res</source>
            <year>2015</year>
            <volume>4</volume>
            <pub-id pub-id-type="pmid">26918144</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28290.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Simons</surname>
                <given-names>FE</given-names>
              </name>
              <name>
                <surname>Ebisawa</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sanchez-Borges</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Thong</surname>
                <given-names>BY</given-names>
              </name>
              <name>
                <surname>Worm</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tanno</surname>
                <given-names>LK</given-names>
              </name>
              <name>
                <surname>Lockey</surname>
                <given-names>RF</given-names>
              </name>
              <name>
                <surname>El-Gamal</surname>
                <given-names>YM</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>SG</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>HS</given-names>
              </name>
              <name>
                <surname>Sheikh</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>2015 update of the evidence base: World Allergy Organization anaphylaxis guidelines.</article-title>
            <source>World Allergy Organ J</source>
            <year>2015</year>
            <volume>8</volume>
            <issue>1</issue>
            <fpage>32</fpage>
            <pub-id pub-id-type="pmid">26525001</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28290.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Healy</surname>
                <given-names>DP</given-names>
              </name>
              <name>
                <surname>Sahai</surname>
                <given-names>JV</given-names>
              </name>
              <name>
                <surname>Fuller</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Polk</surname>
                <given-names>RE</given-names>
              </name>
            </person-group>
            <article-title>Vancomycin-induced histamine release and "red man syndrome": comparison of 1- and 2-hour infusions.</article-title>
            <source>Antimicrob Agents Chemother</source>
            <year>1990</year>
            <month>Apr</month>
            <volume>34</volume>
            <issue>4</issue>
            <fpage>550</fpage>
            <page-range>550-4</page-range>
            <pub-id pub-id-type="pmid">1693055</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28290.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sahai</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Healy</surname>
                <given-names>DP</given-names>
              </name>
              <name>
                <surname>Garris</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Berry</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Polk</surname>
                <given-names>RE</given-names>
              </name>
            </person-group>
            <article-title>Influence of antihistamine pretreatment on vancomycin-induced red-man syndrome.</article-title>
            <source>J Infect Dis</source>
            <year>1989</year>
            <month>Nov</month>
            <volume>160</volume>
            <issue>5</issue>
            <fpage>876</fpage>
            <page-range>876-81</page-range>
            <pub-id pub-id-type="pmid">2572652</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
